Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

An Excess of "Access"?

Nov 01 2006

• By Michael McCaughan

Related Content

Isoflavone Supplement Hot Flash Reduction Similar To Placebo – JAMA Study

Jul 14 2003

Flying Through FDA: Test Runs For Pilot 1

Oct 01 2005

Medicare's Privileged Drug Classes: Price Protections Through 2007

Mar 01 2006

AstraZeneca Rx Promotions Subject Of U.S. Attorney Investigation

Mar 24 2006

Crest Pro-Health Campaign Promotes Multiple Benefits Of Toothpaste

Aug 21 2006

Forest’s Desmoteplase Stroke Study Halted Due To Safety Signal

Oct 25 2006

Reimbursing Designer Drugs

Oct 01 2006

Part D Pricing and Subpoena Power: What the November Elections Could Mean for Wall Street

Oct 01 2006

Crest Pro-Health Benefits Squeezed Into Whitening Toothpaste

Jun 26 2006

Generic Zocor Prompts Some Part D Plans To Make Formulary Adjustments

Jun 26 2006

Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned

Jun 26 2006

Rituxan Adds Third NHL Indication In 2006

Oct 02 2006

Amgen Vectibix Cap Cuts Patient Cost, But Will Payers Balk At High Price?

Oct 02 2006

FDA Drug Safety Reforms Not Enough To Fix Problems, IoM Committee Says

Oct 02 2006

Phenylephrine Efficacy Will Be Questioned In Citizen Petition

Oct 02 2006

Naproxen Fares Better Than Ibuprofen In Cardiovascular-Risk Data

Oct 02 2006

FTC Clears Barr’s Acquisition Of Pliva Based On Divestiture Of Generic Drugs

Oct 23 2006

Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal

Oct 23 2006

Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says

Feb 06 2006

After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight

Jun 19 2006

GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale

May 22 2006

CMS' Change of Heart: Niaspan will be Covered Under Medicare Part D

May 01 2006

J&J Picks Up Listerine, Nicorette With $16.6 Bil. Purchase Of Pfizer OTCs

Jul 03 2006

Colgate-Palmolive Acquires Tom’s Of Maine In $100 Mil. Deal

Mar 27 2006

Barr’s Rationale For Pliva Merger: Business Synergy, Biogenerics Leadership

Jul 03 2006

Polyphenon E User Fee Date Extended To October

Jul 03 2006

Preparing for Year Two of Part D: CMS Puts a Premium on Stability

Jul 01 2006

No "Phase Zero" for Biotech?

Jul 01 2006

Oral Phenylephrine An “Ineffective” Replacement For PSE – Pharmacists

Jul 31 2006

Neurodex Faces Review Prolongation Due To QT Submission

Jun 20 2006

Merck’s Gardasil Records $70 Mil. In Sales In Q3

Oct 20 2006

InterMune Settles Medicaid/Medicare Fraud Charges For $36.9 Mil.

Oct 27 2006

Plavix Injunction Ruling Will Include Irreparable Harm Interpretation

Aug 22 2006

Andrx Divests Oral Contraceptive ANDAs To Teva

Mar 17 2006

GSK Urges FDA Crackdown On Unsubstantiated Weight-Loss Claims

Aug 08 2005

Supplement Labeling Safety One Of Six Guidance Topics Raised By GAO

Jul 17 2000

Playing Offense in Part D: Three Aggressive Medicare Strategies Demand Pharma Attention

Dec 01 2005

Novo Nordisk Levemir To Launch Within Next 12 Months

Jun 17 2005

Desmoteplase Approval For Stroke Expected In 2009, Forest Says

Mar 16 2005

Graham Meta-Analysis Ultimately Positive For Celebrex, Bextra

Mar 07 2005

FDA Intervention In Kava Labeling Suit Sought By Jarrow Formulas

Oct 21 2002

The Perils of Part D

Jan 01 2006

Plavix Patent Infringement Trial Set For Jan. 22

Sep 01 2006

Getting Personal: FDA's Plan to Save the Drug Industry

Sep 01 2006

Boehringer Hits Above The Belt With Zantac Purchase

Oct 16 2006

Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing

Oct 09 2006

Cortex’ Clinical Hold On CX717 Lifted By FDA

Oct 09 2006

XanGo Brochures Draw FDA Warning Letter For Unsubstantiated Claims

Oct 09 2006

Awaiting The Part D Shakeout

Apr 01 2006

Part D: A Big Chance for Small PBMs

Apr 01 2006

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window